Loading stock data…
VolitionRx Limited (VNRX)
$1.00-0.08 (-7.41%)
Market ClosedLast close Jul 24
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
VolitionRx Limited in the Healthcare sector is trading at $1.00 with a market capitalization of $18M. Wall Street consensus targets $16.97 (5 analysts), implying a +1596.6% move over the next 12 months. The stock is currently near its 52-week low of $0.99, remaining 77.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +1596.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $985,076↑ | $447,034↓ | $627,277↑ | $406,688↑ | $246,385 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.23M↓ | -$4.73M↑ | -$4.87M↑ | -$6.22M↓ | -$5.40M |
| Net Income | -$6.66M↓ | -$6.27M↓ | -$5.38M↑ | -$6.28M↓ | -$5.42M |
Peer Comparison
JNJUNHPFE
Fundamentals
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$17.61M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
76.93%
Volume
Today's trading volume
161,117
Recent News
VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution
The price target for VolitionRx has been reset from around US$2.20 to roughly US$16.97 per share, marking a major change in how the stock is being framed in recent research. This shift reflects a clear split between analysts who focus on potential execution across the Nu.Q portfolio and others who prefer to keep expectations and assigned value more restrained for now. As you read on, you will see how this evolving narrative may shape the way you track VolitionRx from here. Stay updated as the...
VolitionRx Limited (VNRX): 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts
With an upside potential of 1451.32%, VolitionRx Limited (NYSEAMERICAN:VNRX) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 15, Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx Limited (NYSEAMERICAN:VNRX), stated that the company made substantial progress across multiple product platforms during the first quarter and following quarter-end […]
VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
VolitionRX Ltd (VNRX) reports a 300% revenue increase and expands its global network, despite rising expenses and ongoing commercialization challenges.
VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
VolitionRX Ltd (VNRX) reports a 133% year-on-year revenue growth and significant partnerships, despite ongoing financial challenges and unpredictable revenue streams.
VolitionRx Limited Q4 2025 Earnings Call Summary
Moby summary of VolitionRx Limited's Q4 2025 earnings call